Skip to main content

Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension

  • Sponsored by UCB Pharma
Feb 01, 2024 9:00 am

#navpanes=0&scrollbar=0